Mpox in the Emergency Department

AbstractPurpose of ReviewThis paper provides a comprehensive review of mpox for emergency medicine providers. Despite the disease existing in endemic regions for decades, substantial knowledge gaps remain. This review covers the diagnosis, treatment, and prevention of mpox.Recent FindingsSince the 2022 outbreak began, there have been more than 80,000 cases of mpox. The disease manifests as a rash in most cases. Diagnosis is challenging due to the great variability in rash presentation and similarity with other cutaneous diseases, however, PCR testing can confirm mpox. Antiviral therapies are available under a compassionate use protocol for severe cases. Vaccines are available for those with exposure or at high risk for exposure.SummaryLimited preliminary data suggest effectiveness of some antiviral therapies and vaccines. Ongoing studies will determine their safety and efficacy. Emergency medicine providers must remain up to date regarding these studies to provide appropriate treatment and prevent the spread of mpox.
Source: Current Emergency and Hospital Medicine Reports - Category: Emergency Medicine Source Type: research